News about Market

Yao Pharma and Pfizer Sign Exclusive Collaboration Deal

Yao Pharma has entered into an exclusive global licensing agreement with Pfizer, granting rights to develop, manufacture, and commercialise its oral small-molecule GLP-1 receptor agonists, including lead candidate YP05002. The partnership aims to advance next-generation metabolic therapies with worldwide reach.

Market | 10/12/2025 | By Akanki |  209

Hikma Launches TYZAVAN in US

Hikma has launched TYZAVAN in the US, introducing a glycopeptide antibacterial in pre-filled, ready-to-use bags designed to streamline hospital workflows and support faster and safer treatment.

Market | 09/12/2025 | By Akanki |  284

Covestro and Allmed Partner to Recycle Artificial Kidney Filters

Covestro and Allmed have launched a feasibility study to explore recycling pathways for artificial kidney filters, bringing together Kimal, hospitals, and recycling partners to build a full medical plastics recycling ecosystem.

Market | 09/12/2025 | By Akanki |  220

L'Oreal to Double Its Equity Stake in Galderma as Strategic Partnership Deepens

Galderma Group AG, the pure-play leader in the dermatology category, announced that L’Oréal Groupe plans to increase its equity investment in the company by acquiring an additional 10 percent stake from Sunshine SwissCo GmbH, a consortium led by EQT, the Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd. as the sellers.

Market | 09/12/2025 | By Darshana |  462

Convergen Raises USD 10 Million Seed Funding to Advance TrimTAC Platform

Convergen has raised USD 10 million in seed funding from Qiming Venture Partners to speed up development of its TrimTAC platform—novel TRIM21-based bifunctional degraders—and advance its early pipeline targeting neurodegenerative and other high-need diseases.

Market | 09/12/2025 | By Akanki |  287

CLINUVEL Grows Singapore RD&I Hub to Advance Peptide Innovation

CLINUVEL is expanding its VALLAURIX Research, Development & Innovation Centre in Singapore to strengthen its work on next-generation peptide therapies. The five-year, EDB-supported investment will enhance facilities, accelerate development of liquid long-acting drug delivery platforms, and allow RD&I teams to advance late-stage programmes.

Market | 08/12/2025 | By Dineshwori |  249

Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon

Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.

Market | 08/12/2025 | By Dineshwori |  181

Virax Biolabs Closes USD 5 Million Private Placement

Virax Biolabs has closed a USD 5 million private placement, extending its cash runway into the first half of 2028 and supporting ongoing regulatory studies for its ViraxImmune platform, including long COVID and post-acute infection syndrome programmes, alongside planned FDA and MHRA submissions and platform expansion initiatives.

Market | 06/12/2025 | By Dineshwori |  362

Sanofi Completes Vicebio Takeover

This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology.

Market | 05/12/2025 | By Darshana |  195

Lupin and Valorum Enter into Licensing Agreement for Armlupeg in US

Under the terms of the agreement, Valorum will advance the commercialisation and distribution of Armlupeg (pegfilgrastim-unne) in the US. Lupin will be responsible for manufacturing and supply of the product and will receive an upfront licence fee and a royalty payment on net sales.

Market | 05/12/2025 | By Dineshwori |  191